Effect of the Multi‐Strain Probiotic SYN‐53 in the Management of Allergic Rhinoconjunctivitis

IF 12.6 1区医学 Q1 ALLERGY

Allergy Pub Date : 2025-06-27 DOI:10.1111/all.16634

Karl‐Christian Bergmann, Torsten Zuberbier

{"title":"Effect of the Multi‐Strain Probiotic SYN‐53 in the Management of Allergic Rhinoconjunctivitis","authors":"Karl‐Christian Bergmann, Torsten Zuberbier","doi":"10.1111/all.16634","DOIUrl":null,"url":null,"abstract":"Dysbiosis is increasingly linked to allergy development. This study evaluates the efficacy of the multi‐strain probiotic SYN‐53 in the management of allergic rhinoconjunctivitis (ARC). Eighty‐four subjects with confirmed grass pollen allergy underwent up to three bi‐weekly 3‐day intake cycles with SYN‐53 or placebo. After each cycle, subjects were exposed to grass pollen in an allergen exposure chamber. ARC symptoms were assessed using the Total Symptom Score (TSS) before and after each use of SYN‐53. After one intake cycle, SYN‐53 already showed a trend towards greater efficacy over placebo, which became significant after two cycles (ΔTSSMAX: −3.44 ± 0.42 vs. −1.87 ± 0.37; p = 0.0067), with 38% vs. 24% symptom relief. In subjects with moderate to severe symptoms, SYN‐53 was already significantly superior after one single intake cycle and improved further after two cycles (ΔTSSMAX: −4.78 ± 0.51 vs. −2.43 ± 0.47; p = 0.0014), with 45% vs. 26% symptom relief. SYN‐53 is effective in the management of ARC, highlighting the role of bacterial diversity and dosage in probiotic nutritional supplements.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"26 1","pages":""},"PeriodicalIF":12.6000,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Allergy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/all.16634","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 0

Abstract

Dysbiosis is increasingly linked to allergy development. This study evaluates the efficacy of the multi‐strain probiotic SYN‐53 in the management of allergic rhinoconjunctivitis (ARC). Eighty‐four subjects with confirmed grass pollen allergy underwent up to three bi‐weekly 3‐day intake cycles with SYN‐53 or placebo. After each cycle, subjects were exposed to grass pollen in an allergen exposure chamber. ARC symptoms were assessed using the Total Symptom Score (TSS) before and after each use of SYN‐53. After one intake cycle, SYN‐53 already showed a trend towards greater efficacy over placebo, which became significant after two cycles (ΔTSSMAX: −3.44 ± 0.42 vs. −1.87 ± 0.37; p = 0.0067), with 38% vs. 24% symptom relief. In subjects with moderate to severe symptoms, SYN‐53 was already significantly superior after one single intake cycle and improved further after two cycles (ΔTSSMAX: −4.78 ± 0.51 vs. −2.43 ± 0.47; p = 0.0014), with 45% vs. 26% symptom relief. SYN‐53 is effective in the management of ARC, highlighting the role of bacterial diversity and dosage in probiotic nutritional supplements.

查看原文本刊更多论文

多菌种益生菌SYN - 53在变应性鼻结膜炎治疗中的作用

生态失调与过敏的关系越来越密切。本研究评估了多菌株益生菌SYN - 53在变应性鼻结膜炎（ARC）治疗中的疗效。84名确诊对草花粉过敏的受试者接受了SYN - 53或安慰剂的三次双周3天的摄入周期。每个周期后，受试者在过敏原暴露室中暴露于草花粉。在每次使用SYN‐53前后使用总症状评分（TSS）评估ARC症状。在一个摄入周期后，SYN‐53已经显示出比安慰剂更有效的趋势，在两个周期后变得显著(ΔTSSMAX:−3.44±0.42 vs−1.87±0.37；P = 0.0067)，症状缓解38% vs. 24%。在有中度至重度症状的受试者中，SYN‐53在单次摄入周期后已经显著优于对照组，并在两个周期后进一步改善(ΔTSSMAX:−4.78±0.51 vs.−2.43±0.47；P = 0.0014)，症状缓解45% vs 26%。SYN‐53在ARC的管理中是有效的，强调了益生菌营养补充剂中细菌多样性和剂量的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Allergy 医学-过敏

CiteScore

26.10

自引率

9.70%

发文量

393

审稿时长

2 months

期刊介绍： Allergy is an international and multidisciplinary journal that aims to advance, impact, and communicate all aspects of the discipline of Allergy/Immunology. It publishes original articles, reviews, position papers, guidelines, editorials, news and commentaries, letters to the editors, and correspondences. The journal accepts articles based on their scientific merit and quality. Allergy seeks to maintain contact between basic and clinical Allergy/Immunology and encourages contributions from contributors and readers from all countries. In addition to its publication, Allergy also provides abstracting and indexing information. Some of the databases that include Allergy abstracts are Abstracts on Hygiene & Communicable Disease, Academic Search Alumni Edition, AgBiotech News & Information, AGRICOLA Database, Biological Abstracts, PubMed Dietary Supplement Subset, and Global Health, among others.